CNBC on MSN23d
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
Flynn: Eli Lilly could capture a significant part of a $100 billion market with Zepbound.
Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...
Eli Lilly and Company (NYSE:LLY) Shares Acquired by Czech National Bank
Czech National Bank boosted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 6.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange ...
FiercePharma11d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
The company is also testing tirzepatide in heart failure ... said in the report. “Now with Zepbound, the revolution ...
Mediar Therapeutics signs licensing deal with Eli Lilly for IPF treatment
Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point
Chris Schott, an analyst from J.P. Morgan, maintained the Buy rating on Eli Lilly & Co (LLY – Research Report). The associated price target ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
While Eli Lilly and Company ( NYSE:LLY ) shareholders are probably generally happy, the stock hasn't had particularly... The U.S. Food and Drug Administration (FDA) recently approved Zepbound ...